AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9761434
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no UFT administered to 557 patients)
Trial: 7642053
Drug: Fibrinolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinolytic therapy (thrombolysis) for AMI
Trial: 26337626
Drug: Progressive multicomponent
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Progressive multicomponent intervention (home-based progressive strength, mobility and activities of daily living training)
Trial: 19665606
Drug: MF59-adjuvanted H5N1
RxNorm normalized name: Influenza A monovalent (H5N1), ADJUVANTED-2013
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59-adjuvanted H5N1 clade 1 subunit vaccine
Trial: 19665606
Drug: Plain H5N1
RxNorm normalized name: influenza, H5N1-1203
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain H5N1 clade 1 subunit vaccine
Trial: 17659909
Drug: High-protein diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein diet (2.0 g protein/kg/day)
Trial: 17659909
Drug: Low-protein diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-protein diet (0.5 g protein/kg/day)
Trial: 27703067
Drug: Fibrin gel
RxNorm normalized name: thrombin
DrugBank: Fibrin (DB16604)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin gel
Trial: 11895913
Drug: Sequential methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sequential methotrexate and 5‐fluorouracil (MF)
Trial: 10362116
Drug: Melatonin 40
RxNorm normalized name: vit B/folic acid/calcium/soy xt/black cohosh xt/melatonin 400 mcg-125 mg-62 mg-40 mg (day)/175 mg-62 mg-1 mg (night) ORAL CAPSULE, SEQUENTIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 40 mg orally for 21 days
Trial: 1788754
Drug: Intravenous PGE1
RxNorm normalized name: PGE1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous PGE1
Trial: 1788754
Drug: Intravenous Pentoxifylline
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Pentoxifylline
Trial: 7259364
Drug: Placebo (isotonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (isotonic glucose solution)
Trial: 31653513
Drug: anti-PCSK9 monoclonal
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: anti-PCSK9 monoclonal antibodies (mAbs) alirocumab or evolocumab
Trial: 30152298
Drug: Supported 6-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supported 6-week online intervention based on cognitive behavioural therapy (iCBT)
Trial: 25698197
Drug: DDAVP (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDAVP (0.3 μg/kg) administered intravenously during re-warming
Trial: 25698197
Drug: Control (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (saline administered intravenously during re-warming)
Trial: 18223031
Drug: Rosiglitazone vs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone vs Metformin
Trial: 10817086
Drug: Cerivastatin 0.3
RxNorm normalized name: cerivastatin 0.3 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerivastatin 0.3 mg
Trial: 9737646
Drug: Gemfibrozil 1200
RxNorm normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gemfibrozil 1200 mg
Trial: 3071952
Drug: Orchiectomy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orchiectomy plus Anandron (300 mg daily)
Trial: 29293181
Drug: Intermittent boluses
RxNorm normalized name: phenylbutazone
DrugBank: Phenylbutazone (DB00812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent boluses (21 mL/3 h) of 0.2% ropivacaine
Trial: 29293181
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion (7 mL/h) of 0.2% ropivacaine
Trial: 27669730
Drug: ATG+G-CSF
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATG+G-CSF
Trial: 24070164
Drug: FOLFOX-4 regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX-4 regimen (oxaliplatin 85 mg/m², leucovorin 200 mg/m², 5-FU bolus 400 mg/m², 5-FU infusion 600 mg/m²) administered every 2 weeks for two consecutive days.
Trial: 19940093
Drug: 3% carbohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% carbohydrate solution with electrolytes
Trial: 19940093
Drug: 6% carbohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% carbohydrate solution with electrolytes
Trial: 19940093
Drug: 12% carbohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12% carbohydrate solution with electrolytes
Trial: 16253026
Drug: Helicobacter pylori
RxNorm normalized name: HELICOBACTER PYLORI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Helicobacter pylori eradication therapy
Trial: 12020181
Drug: Symptom-triggered treatment
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptom-triggered treatment with oxazepam
Trial: 12020181
Drug: Fixed-schedule treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-schedule treatment with oxazepam
Trial: 10219832
Drug: Plastic flakes
RxNorm normalized name: polyethylene glycol 3350
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plastic flakes (24 g/day)
Trial: 10219832
Drug: Small granules
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small granules (24 g/day)
Trial: 2145400
Drug: Ondansetron (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (0.15 mg/kg IV)
Trial: 7206593
Drug: diatrizoate with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diatrizoate with added calcium (11.3 mmol/l)
Trial: 27789095
Drug: Aspirin 325
RxNorm normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 325 mg twice a day (BID) for 4 weeks
Trial: 27789095
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and Lovenox in conjunction with pneumatic compression devices (from a recent randomized controlled trial)
Trial: 11180024
Drug: Ketoconazole 400
RxNorm normalized name: ketoconazole 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole 400 mg once daily
Trial: 11417442
Drug: Rifampicin 600
RxNorm normalized name: Rifampicin 600 mg powder for solution for infusion vial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin 600 mg once daily
Trial: 11180024
Drug: Ketoconazole 200
RxNorm normalized name: ketoconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole 200 mg once daily
Trial: 9924266
Drug: Lutein supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutein supplementation (15 mg/d as mixed ester forms) for 4 months
Trial: 30224533
Drug: Oral rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rifampin 10 mg/kg (450 mg)
Trial: 30224533
Drug: Oral rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rifampin 20 mg/kg (900 mg)
Trial: 30224533
Drug: Oral rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rifampin 30 mg/kg (1,350 mg)
Trial: 30224533
Drug: Oral rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rifampin (all doses)
Trial: 30224533
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of rifampin
Trial: 21586501
Drug: Social Effectiveness
RxNorm normalized name: Safety 1st Social Safety Pack KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social Effectiveness Therapy for Children (SET‐C)
Trial: 8694013
Drug: Control supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control supplement containing phosphate and vitamins
Trial: 1304482
Drug: Single carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single carboplatin (cp) at the dose of 260‐410 mg/m2
Trial: 1304482
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy of carboplatin (cp) at a dose of 180‐350 mg/m2 plus adriamycin and cyclophosphamide
Trial: 1304482
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy of carboplatin (cp) plus adriamycin and cyclophosphamide
Trial: 3534333
Drug: Lovastatin (mevinolin)
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lovastatin (mevinolin) 40 mg twice a day
Trial: 30172864
Drug: Hyoscine Butylbromide
RxNorm normalized name: Hyoscine butylbromide
DrugBank: Butylscopolamine (DB09300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine Butylbromide (HB) administered once DR occurs (Group 1)
Trial: 25348244
Drug: APAP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APAP treatment
Trial: 19664296
Drug: Trehalose (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trehalose (75 g carbohydrate equivalents)
Trial: 19664296
Drug: Glucose (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose (75 g carbohydrate equivalents)
Trial: 15020035
Drug: Experimental agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental agent (exact agent not specified)
Trial: 11686541
Drug: Aldosterone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldosterone (0.5 mg) during normoxia (FiO2=0.21)
Trial: 17663307
Drug: Arginine vasopressin
RxNorm normalized name: 1-deamino-8-D-arginine vasopressin
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arginine vasopressin receptor antagonists
Trial: 11706714
Drug: Phlogenzym (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phlogenzym (3 times 3 tablets for the first three days, then 3 times 2 tablets)
Trial: 11706714
Drug: Standard antioedematous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antioedematous drugs based on aescin (control group)
Trial: 9706373
Drug: New slow-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New slow-release tablet formulation (Pindac)
Trial: 9706373
Drug: Standard slow-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard slow-release capsule formulation
Trial: 27627817
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg aspirin before surgery and 100 mg daily for up to 30 days after surgery
Trial: 27627817
Drug: Placebo before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo before surgery and placebo daily for up to 30 days after surgery
Trial: 27627817
Drug: Aspirin (pooled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (pooled analysis)
Trial: 24478190
Drug: Iodixanol 270
RxNorm normalized name: IODIXANOL 270mgI/ml INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodixanol 270 mg iodine pro ml
Trial: 24478190
Drug: Ioversol 320
RxNorm normalized name: IOVERSOL 320MG/ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ioversol 320 mg iodine pro ml
Trial: 20401355
Drug: Glutamate (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamate (1.0 mol/L) injection
Trial: 20401355
Drug: Co-injection of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-injection of NMDA antagonist ketamine (10 mmol/L)
Trial: 11711256
Drug: Azithromycin oral
RxNorm normalized name: azithromycin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin oral suspension, 10 mg/kg once daily for 3 days
Trial: 3980239
Drug: Educational program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational program for family members including counseling and a booklet on supporting medication compliance, appointment keeping, diet, and weight control.
Trial: 27958622
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of intravenous ampicillin every 6 hours
Trial: 27958622
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of intravenous ampicillin every 6 hours
Trial: 8394538
Drug: Conventional immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional immunotherapy
Trial: 20207497
Drug: High-dose radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose radiation (79.2 GyE)
Trial: 17261244
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of three drugs from two different classes (2 nucleosides or nucleotide analogs (NRTI) plus 1 non‐nucleoside (NNRTI) or 1 boosted protease inhibitor (PI/r))
Trial: 17261244
Drug: Delay of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delay of therapy in patients with CD4+ counts of > 350 cells/microl
Trial: 17261244
Drug: Adherence to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherence to therapy
Trial: 17261244
Drug: Individualized approach
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized approach to therapy
Trial: 9491833
Drug: Continuous transdermal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous transdermal oestradiol (50 microg daily)
Trial: 9491833
Drug: Transdermal oestradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal oestradiol (50 microg daily) and medroxyprogesterone acetate (10 mg daily for the first 12 days of each month)
Trial: 7942414
Drug: Anticoagulant drugs
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant drugs
Trial: 31989155
Drug: High-dose DCB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose DCB (In.Pact™)
Trial: 31989155
Drug: Low-dose DCB
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose DCB (Ranger™)
Trial: 25640628
Drug: RT plus
RxNorm normalized name: Recort Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT plus standard-dose cisplatin and 5-fluorouracil (SDPF) chemotherapy (arm A)
Trial: 25640628
Drug: RT plus
RxNorm normalized name: Recort Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT plus low-dose cisplatin and 5-fluorouracil (LDPF) chemotherapy (arm B)
Trial: 15956927
Drug: Adenosine (Ado)
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine (Ado) infusion over 10 min at systemic pressure during IAC bypass surgery
Trial: 15956927
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion over 10 min at systemic pressure during IAC bypass surgery
Trial: 11172846
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg esterified estrogen
Trial: 21077506
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg conjugated equine estrogen
Trial: 9644978
Drug: Doxazosin 4-8
RxNorm normalized name: doxazosin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin 4-8 mg (mean 5.7 mg)
Trial: 27856335
Drug: Active grape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active grape formulation
Trial: 27856335
Drug: Placebo (formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (formulation free of polyphenols)
Trial: 17122241
Drug: Single-injection technique
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-injection technique (Group S) with 25 mL of mepivacaine 1%
Trial: 17122241
Drug: Double-injection technique
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-injection technique (Group D) with 12.5 mL of mepivacaine 1% injected twice
Trial: 9692413
Drug: Controlled-release low
RxNorm normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release low dose aspirin (75 mg)
Trial: 9692413
Drug: Conventional formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional formulation aspirin (75 mg)
Trial: 7837399
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose epidural fentanyl (HEF)
Trial: 9084455
Drug: 10 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/m2 dose of pegylated-liposomal doxorubicin for the first cycle, followed by 20 mg/m2 every 3 weeks
Trial: 9084455
Drug: 20 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/m2 dose of pegylated-liposomal doxorubicin every 3 weeks
Trial: 31543516
Drug: Calcium intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium intake with Ca:Mg ratio between 1.7 and 2.5
Trial: 26355169
Drug: Calcium‐incorporated implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium‐incorporated implants (Xpeed)
Trial: 23342969
Drug: Brassica rapa
RxNorm normalized name: BRASSICA RAPA POLLEN
DrugBank: Brassica rapa pollen (DB10942)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brassica rapa ethanol extract (BREE) 2 g/day
Trial: 21936892
Drug: Placebo (starch,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (starch, 2 g/day)
Trial: 18977811
Drug: Oral tizanidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tizanidine (TZD)
Trial: 12370455
Drug: Tricyclic Antidepressants
RxNorm normalized name: TRICYCLIC ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tricyclic Antidepressants (TCA)
Trial: 10187881
Drug: Glucose potassium
RxNorm normalized name: glucose / potassium chloride
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucose potassium insulin (GKI) infusion at 100 mL/h consisting of 16 U human soluble insulin and 20 mmol potassium chloride in 500 mL 10% glucose
Trial: 1854670
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of D3-alpha-tocopheryl acetate for 14 consecutive days (n = 6)
Trial: 1854670
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of D3-alpha-tocopheryl acetate for 14 consecutive days (n = 8)
Trial: 1854670
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg of D3-alpha-tocopheryl acetate for 14 consecutive days (n = 6)
Trial: 29390054
Drug: Weekly irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly irinotecan hydrochloride and docetaxel
Trial: 27349715
Drug: Local liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local liposomal bupivacaine (LB) - 20 mL of bupivacaine/10 mL of saline solution
Trial: 23899039
Drug: Six-monthly monitoring
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Six-monthly monitoring
Trial: 20459820
Drug: Three-monthly monitoring
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-monthly monitoring (Control)
Trial: 18250253
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine (1-minute bolus of 0.26 mg/kg, followed by a maintenance infusion of 0.25 mg/kg/h)
Trial: 18250253
Drug: Pretreatment with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pretreatment with lamotrigine (300 mg)
Trial: 9875583
Drug: Isoniazid (H)
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid (H) 6 months, twice a week
Trial: 9875583
Drug: Rifampicin (R)
RxNorm normalized name: rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifampicin (R) plus Pyrazinamide (Z) 3 months, twice a week
Trial: 1095306
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg diftalone daily for 2 weeks
Trial: 71973
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg indomethacin daily for 2 weeks
Trial: 31888740
Drug: n‐3 PUFA‐enriched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n‐3 PUFA‐enriched medium/long‐chain triglyceride (MCT/LCT) ILE (Lipidem/Lipoplus® 200 mg/ml, B. Braun Melsungen AG)
Trial: 20497239
Drug: DHEA 25
RxNorm normalized name: GNP DHEA 25mg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA 25 mg/day p.o. for 6 months
Trial: 20497239
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no hormone replacement)
Trial: 18257399
Drug: Sequential chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemotherapy and radiation therapy
Trial: 18257399
Drug: Sequential chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemotherapy and surgery
Trial: 10714612
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg diclofenac‐Na effervescent (fast-release NSAID)